1-18 of 18 Results

Title Investigator Disease(s)

A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy

[Protocol 18-1078]
Henry Fung
  • Non-Hodgkin's Lymphoma
  • Assessing Romidepsin + Adcetris in Pts with Requiring Systemic Therapy for Cutaneous T-cell Lymphoma

    [Protocol 16-1009]
    Nadia Khan
  • Non-Hodgkin's Lymphoma
  • Assessing Yescarta in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (INHL)

    [Protocol 17-1031]
    Henry Fung
  • Non-Hodgkin's Lymphoma
  • Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

    [Protocol 18-1032]
    Aysa Varshavsky
  • Non-Hodgkin's Lymphoma
  • Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies

    [Protocol 18-1064]
    Henry Fung
  • Multiple
  • Gazyva and/or Rituxan + Polatuzumab Vedotin and Venetoclax for Relapsed/Refractory Lymphoma

    [Protocol 16-1037]
    Nadia Khan
  • Non-Hodgkin's Lymphoma
  • Imbruvica autologous stem cell transplantation vs placebo in pts w/ large B cell lymphoma

    [Protocol 16-2006]
    Henry Fung
  • Hodgkin's Lymphoma
  • Ipilimumab +/- Nivolumab and Brentuximab Vedotin in Pts with Relapsed/Refractory Hodgkin Lymphoma

    [Protocol 15-2004]
    Henry Fung
  • Hodgkin's Lymphoma
  • Ixazomib +/- Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma

    [Protocol 18-1011]
    Carlyn Rose Tan
  • Multiple Myeloma
  • KTE-X19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia

    [Protocol 18-1065]
    Henry Fung
  • Leukemia, other
  • Molecular Analysis for Therapy Choice (MATCH)

    [Protocol 15-7002]
    Lori Goldstein
  • Multiple
  • Molecular Monitoring w/Circulating Tumor DNA and Opdivo Maintenance in Diffuse Large B-Cell Lymphoma

    [Protocol 17-1062]
    Nadia Khan
  • Non-Hodgkin's Lymphoma
  • ONC201 in Relapsed/Refractory Multiple Myeloma

    [Protocol 15-1060]
    Carlyn Rose Tan
  • Multiple Myeloma
  • Oral VRx-3996 + Valganciclovir in Pts w/Epstein-Barr Virus-Associated Lymphoid Malignancies

    [Protocol 17-1071]
    Carlyn Rose Tan
  • Multiple
  • RO7082859 +/- Rituximab (R) or Obinutuzumab (G) + CHOP in Participants With RR Non-Hodgkin Lymphoma

    [Protocol 18-1080]
    Henry Fung
  • Non-Hodgkin's Lymphoma
  • Risk Assessment Program (RAP) Registry

    [Protocol IRB09831]
    Mary Daly
  • Multiple
  • Study of Venetoclax plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

    [Protocol 17-1017]
    Nadia Khan
  • Non-Hodgkin's Lymphoma
  • Tissue Acquisition for Analysis of HIV-1 Associated Malignancies

    [Protocol 15-9041]
    Deric Savior
  • Multiple